Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.

Related Articles

Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.

Hell J Nucl Med. 2017 Nov 27;:

Authors: Sachpekidis C, Hassel JC, Dimitrakopoulou-Strauss A

Abstract
Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After completion of the concurrent ipilimumab and vemurafenib administration, a third 18F-FDG PET/CT showed an impressive metabolic remission of the metastatic disease, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving combination therapies.

PMID: 29177265 [PubMed - as supplied by publisher]

http://ift.tt/2AiYXVT